Evidence‑based cardiovascular risk assessment tool. Compute LDL-C, non‑HDL cholesterol, TC/HDL ratio, and guideline‑aligned risk category using your lipid panel.
Low‑density lipoprotein (LDL) cholesterol is often called "bad cholesterol" because elevated levels promote atherosclerotic plaque formation, increasing risk for coronary artery disease, stroke, and peripheral artery disease. According to the 2018 ACC/AHA Blood Cholesterol Guideline, LDL reduction is a primary target for primary and secondary prevention. This calculator implements two validated estimation methods:
Each 1 mmol/L (≈38.7 mg/dL) reduction in LDL is associated with ~22% decrease in major cardiovascular events (CTT meta‑analysis). The calculator displays risk category aligned with ESC/EAS 2019 and ACC/AHA thresholds: Optimal (<70 mg/dL for high‑risk patients), Near Optimal (70–99), Borderline High (100–129), High (130–159), and Very High (≥160). Non‑HDL cholesterol (TC minus HDL) is a secondary predictor, with recommended target <100 mg/dL for high‑risk individuals.
Friedewald underestimates LDL when TG > 400 mg/dL; in such cases direct LDL measurement is advised. The Martin-Hopkins equation (full version) offers better precision for TG levels up to 800 mg/dL. However, this tool uses a simplified, TG‑range‑based factor that is not clinically validated. It is intended for educational illustration only. Always confirm abnormal results with a direct LDL‑C test or laboratory measurement.
A 55‑year‑old with hypertension, TC = 210 mg/dL, HDL = 42 mg/dL, TG = 165 mg/dL. Friedewald LDL = 210 − 42 − (165/5) = 135 mg/dL → Borderline high. Non‑HDL = 168 mg/dL. TC/HDL ratio = 5.0 (moderate risk). Using Martin-Hopkins: factor for TG 165 is ~5.2 → LDL ≈ 210 − 42 − (165/5.2) ≈ 136.3 mg/dL. Clinical recommendation: lifestyle modification + statin if 10‑year ASCVD risk >7.5%. The tool’s classification matches current guidelines.
| Category | LDL Range (mg/dL) | Recommendation (based on AHA/ACC) |
|---|---|---|
| Optimal / Very High Risk | < 70 | Target for secondary prevention or very high ASCVD risk. |
| Near Optimal / Above Optimal | 70 – 99 | Acceptable for low‑risk individuals; lifestyle emphasis. |
| Borderline High | 100 – 129 | Consider risk enhancers; moderate‑intensity statin if risk >7.5%. |
| High | 130 – 159 | Moderate to high‑intensity statin often indicated. |
| Very High | ≥ 160 | High‑intensity statin ± ezetimibe; aggressive management. |
Friedewald underestimates LDL by up to 10–15% when TG > 200 mg/dL and in patients with diabetes or chronic kidney disease. Martin-Hopkins, developed using the NHANES database, uses 180 different factors for TG / non‑HDL ratios, reducing systematic bias. A 2019 study in JACC confirmed that Martin-Hopkins reclassifies 12–15% of patients into more appropriate risk categories compared to Friedewald. Our calculator implements a simplified factor table (not the full 180‑factor model). For research or clinical use, please refer to the original Martin-Hopkins publication or use direct LDL measurement.